COGNITION THERAPEUTICS INC. - COMMON STOCK

0,4378

25-апреля-25 15:45:00

15 мин. задержка

Акции

-0,0036

-0,82%

Сегодняшний диапазон

0,4203 - 0,4408

ISIN

N/A

Источник

NASDAQ

Cognition Therapeutics Presents Results at AD/PD 2025 Showing Impact of Zervimesine (CT1812) on Alzheimer’s Disease Processes

01 апр 2025 06:30:00 Источник Nasdaq GlobeNewswire
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025

25 мар 2025 06:30:57 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Reports Year End 2024 Financial Results and Provides Business Update

20 мар 2025 06:00:26 Источник Nasdaq GlobeNewswire
Cognition Therapeutics to Report Fourth Quarter and Full Year 2024 Results

13 мар 2025 15:05:30 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Granted Extension to Meet Nasdaq Minimum Bid Price Requirement for Continued Exchange Listing

12 мар 2025 15:05:04 Источник Nasdaq GlobeNewswire
Cognition Therapeutics to Present at Life Sciences Virtual Investor Conference

10 мар 2025 06:30:44 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Publishes Research Supporting the Potential of Zervimesine in Dry AMD

27 фев 2025 06:30:08 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Successfully Passes Pre-defined Futility Analysis of Phase 2 Study of Oral Zervimesine (CT1812) in Geographic Atrophy

26 фев 2025 06:00:00 Источник Nasdaq GlobeNewswire
Cognition Therapeutics’ VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit

25 фев 2025 06:30:40 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Announces Publication of Commercial Manufacturing Process for Lead Alzheimer’s Candidate, Zervimesine (CT1812)

20 фев 2025 06:30:00 Источник Nasdaq GlobeNewswire
Cognition’s Positive Phase 2 ‘SHIMMER’ Study of Zervimesine (CT1812) in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at ILBDC

30 янв 2025 06:30:33 Источник Nasdaq GlobeNewswire
Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

08 янв 2025 15:14:32 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

18 дек 2024 06:22:43 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Announces all Participants have Completed their Final Visits in the Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies

26 ноя 2024 06:30:22 Источник Nasdaq GlobeNewswire
Cognition Therapeutics’ Analysis Correlates Biomarker Changes with Cognitive Benefit in Alzheimer’s Population

25 ноя 2024 06:30:49 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

13 ноя 2024 06:30:45 Источник Nasdaq GlobeNewswire
Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

12 ноя 2024 06:30:38 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

31 окт 2024 15:15:00 Источник Nasdaq GlobeNewswire
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

29 окт 2024 11:55:00 Источник Nasdaq GlobeNewswire
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD

23 окт 2024 06:30:27 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.